Zosano Pharma Announces Proposed Public Offering of Common Stock
August 31 2020 - 4:05PM
Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage
biopharmaceutical company, today announced that it has commenced an
underwritten public offering of shares of its common stock. All of
the shares to be sold in the offering will be offered by Zosano.
The offering is subject to market and other conditions, and there
can be no assurance as to whether or when the offering may be
completed, or the actual size or terms of the offering.
BTIG is the sole book-running manager for the proposed
offering.
A registration statement relating to these securities has been
filed with the U.S. Securities and Exchange
Commission (SEC) and became effective on April 16, 2020.
The offering is being made only by means of a written prospectus
and prospectus supplement that will form a part of the registration
statement. A preliminary prospectus supplement and the accompanying
prospectus relating to the offering will be filed with
the SEC and will be available on the SEC’s website
at www.sec.gov. Alternatively, copies of the preliminary
prospectus supplement and the accompanying prospectus may be
obtained, when available, from BTIG, LLC, 65 East 55th Street,
New York, NY, 10022, by email at equitycapitalmarkets@btig.com or
by telephone at (212) 593-7555.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful, prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Zosano Pharma
Zosano Pharma Corporation is a clinical-stage biopharmaceutical
company focused on developing products where rapid administration
of approved molecules with established safety and efficacy profiles
may provide substantial benefit to patients, in markets where
patients remain underserved by existing therapies. The company’s
transdermal microneedle system technology consists of titanium
microneedles coated with drug that are designed to enable rapid
systemic administration of therapeutics to patients. Zosano’s lead
product candidate is Qtrypta™ (M207), which is a proprietary
formulation of zolmitriptan delivered via its transdermal
microneedle system technology, as an acute treatment for migraine.
The company anticipates that many of its current and future
development programs may enable the company to utilize a regulatory
pathway that has the potential to streamline clinical development
and accelerate the path towards commercialization.
Forward-Looking Statements
To the extent that statements contained in this press release
are not descriptions of historical facts regarding Zosano, they are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve substantial risks and
uncertainties that could cause Zosano’s future results, performance
or achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties related to
market conditions and the completion of the public offering on the
anticipated terms or at all. Zosano undertakes no obligation to
update or revise any forward-looking statements. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to Zosano’s business in
general, please refer to Zosano’s preliminary prospectus supplement
to be filed with the SEC, including the documents incorporated
by reference therein, which include Zosano’s Annual Report on Form
10-K filed with the SEC on March 13, 2020, Zosano’s
Quarterly Reports on Form 10-Q filed with the SEC on May 14, 2020
and August 6, 2020, and Zosano’s other periodic reports filed with
the SEC.
Zosano Contact: Christine Matthews Chief
Financial Officer (510) 745-1200
PR Contact: Sylvia
Wheeler and Alexandra Santos
swheeler@wheelhouselsa.com/asantos@wheelhouselsa.com
Zosano Pharma (NASDAQ:ZSAN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zosano Pharma (NASDAQ:ZSAN)
Historical Stock Chart
From Sep 2023 to Sep 2024